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ABSTRACT 
PURPOSE: There is a paucity of epidemiological data on biopsy-proven renal disease in 
Croatia. The purpose of this report is a review of clinical and histological data, over a period 
of 15 years, from the single biggest adult native renal biopsy centre in Croatia. 
METHODS: This report includes data from 922 adult native renal biopsies in patients referred 
from the whole country and performed in our centre from 1996 till February 2012. Data on 
age, gender, serum creatinine, urine sediment, 24-hour proteinuria, clinical syndrome and 
histological diagnosis were collected and analyzed retrospectively. In all patients light, 
immunofluorescence and electron microscopic analysis was performed.  
RESULTS: The median age of the patients was 48 years (interquartile range 36-59 years), and 
the majority of patients were men (57.8%). The most common indication for renal biopsy was 
nephrotic syndrome (40.3%) followed by asymptomatic urinary abnormalities (31.7%). The 
most common biopsy-proven renal disease in total was IgA glomerulonephritis (19.3%), 
followed by FSGS (15.8%) and membranous glomerulonephritis (9.2%). In men similar 
results were found, while in women the most common were hereditary nephritis (13.4%), 
FSGS (12.9%) and connective tissue disease-related glomerular disorders (11.6%).  
CONCLUSION: The presented data are an important contribution to the better understanding 
of the epidemiology of biopsy-proven renal disease in Croatia and Europe throughout 
comparison with other registry data. This data should be the basis for the formation of 
Croatian Registry of Renal Biopsies. 
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INTRODUCTION 
Renal biopsy is the definitive diagnostic test in patients with renal parenchymal disease. The 
epidemiology of biopsy-proven renal diseases (BPRD) provides useful information about 
prevalence of renal diseases and its clinicopathological correlations. Data provided by renal 
biopsy registries could help better understanding the etiopathological aspects of these 
diseases. These data also make an important foundation for further epidemiological studies 
aimed at identifying relevant risk factors in the development and progression of the renal 
diseases and in developing protocols for preventive medicine. Moreover, combining data with 
renal replacement therapy registries would allow us to evaluate long-term outcome of patients 
with kidney disease [1]. 
Current epidemiological data on BPRD are available from national renal biopsy registries in 
Italy [2, 3], Denmark [4], Brazil [5], Spain [6, 7], Czech Republic [8] and Saudi Arabia [9]. In 
addition, data from local or limited national registries of renal biopsy have been reported from 
South Korea [10, 11], Bahrain [12, 13], Brazil [14], Romania [15], China [16], Finland [17], 
Serbia [18], Pakistan [19] and Belgium [20]. Finally, there are also reports that include 
epidemiological data only on glomerular diseases from Australia [21], Macedonia [22], 
France [23], USA [24], Iran [25], Germany [26], Lebanon [27], Peru [28] and Poland [29]. In 
this study we describe the frequency and clinicopathological correlations of biopsy-proven 
native renal diseases in Croatian adults observed over past 15 years. In Croatia, development 
of national renal biopsy registry is in progress. Our centre renal biopsy registry should serve 
as a foundation of that registry. Dubrava University Hospital is a tertiary care centre situated 
in Zagreb, and adult patients from the whole country are referred to our Nephrology Unit for 
renal biopsy. Our Nephrology Unit has the biggest adult native renal biopsy rate among 
several other Nephrology Units in Croatia, where renal biopsy is performed. Preliminary 
results from our database have been published earlier [30]. 
SUBJECTS AND METHODS 
We retrospectively analyzed the results of adult (≥16 years) native renal biopsies performed at 
our Nephrology Unit from 1996 till the February 2012. Incomplete records, inadequate 
biopsies (where no adequate renal tissue sample was obtained) and some rebiopsies (where 
the primary diagnosis remained unchanged and where there were no signs of different renal 
parenchymal disease in rebiopsy) were excluded from the analysis. 
The data collected for each patient were the date of renal biopsy, age, sex, urine sediment, 
serum creatinine and maximal 24-hour proteinuria till the time of biopsy, as well as all other 
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important laboratory findings and underlying conditions suggesting possible association with 
renal disease. 
The indications for renal biopsy were categorized into following clinical syndromes: 
nephrotic syndrome (NS), asymptomatic urinary abnormalities (AUA), acute nephritic 
syndrome (ANS), chronic nephritic syndrome (CNS) and unexplained renal failure (RF). NS 
was defined as proteinuria ≥3.5g/24 hours. AUA was defined as either hematuria or non-
nephrotic proteinuria (<3.5g/24 hours) or both with normal estimated glomerular filtration 
rate (EGFR) and without any clinical symptoms. ANS was defined as hematuria, 
hypertension, oedema, oliguria and acute reduction of EGFR. CNS was defined as permanent 
(≥6 months) reduction of EGFR (<90ml/minute) with non-nephrotic proteinuria with or 
without hematuria. RF was defined as acute or chronic reduction of EGFR without proteinuria 
and hematuria. The biopsies were done using continuous ultrasound guidance and a 16-gauge 
biopsy needle (Tru-Cut) in an automated gun (Bard Biopsy System
©
). All the biopsies were 
routinely processed for light (hematoxylin and eosin, periodic acid-Schiff, Jones and Masson 
trichrome stains), immunofluorescence (IgG, IgM, IgA, C3, C1q, fibrinogen, albumin, kappa 
and lamda light chains) and also electron microscopy. Pathohistological diagnoses were 
classified into following categories: minimal change disease (MCD), focal segmental 
glomerulosclerosis (FSGS), membranous glomerulonephritis (MGN), IgA glomerulonephritis 
(IgAGN), membranoproliferative glomerulonephritis (MPGN), acute postinfectious 
glomerulonephritis (APINFGN), hereditary nephritis (HERNEF, including Alport’s syndrome 
and thin membrane disease), glomerulonephritis associated with connective tissue diseases 
(CTDGN, systemic lupus erythematosus, Sjögren’s syndrome, sarcoidosis, etc.), anti-GBM 
glomerulonephritis (AGBMGN), pauci-immune glomerulonephritis (PCIMUNGN, including 
focal or diffuse crescentic glomerulonephritis type III or vasculitis), thrombotic 
microangiopathies (TRMAGP, hemolytic-uremic syndrome, thrombotic thrombocytopenic 
purpura, renal scleroderma, malignant hypertension), diabetic nephropathy and metabolic 
diseases (DMETGN), dysgammaglobulinemia associated disorders (DYSGGN, myeloma 
kidney, light or heavy chain deposit disease, cryoglobulinemia), amyloidosis and other renal 
diseases with organized deposits (like fibrillary glomerulonephritis, AMORGDEP), 
nephroangiosclerosis (NAS), acute tubulointerstitial nephritis (ATIN), chronic 
tubulointerstitial nephritis (CTIN), acute tubular injury (ATI; also covers definitive tubular 
necrosis), end stage renal disease (ESRD) and miscellaneous category (including 
mesangioproliferative glomerulonephritis without IgA or IgM deposits, IgM 
glomerulonephritis, C1q nephropathy, etiologically non-differentiable nephropathies, 
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nephronophthisis, nephrocalcinosis, biopsy findings in suspected inherited tubular disorders 
like Bartter, Gitelman or Liddle’s syndrome and normal histopathological findings). 
Data analysis/Statistics 
All analyses were performed using the SPSS statistical software package (version 17.0). 
Continuous variables were expressed as median with interquartile range, and categorical 
variables as frequency and in percentage. 
RESULTS 
Over the study period a total of 951 native renal biopsy records were included in our centre 
registry. After excluding re-biopsies where there was no change in the primary diagnosis from 
initial biopsy, a total of 922 biopsy records were included in our analysis (including 4 re-
biopsies records). All of the patients were Caucasian and ≥16 years old. We observed a 
constantly increasing trend in renal biopsy rate from the year 2003 forward (Figure 1). The 
main clinicoepidemiological characteristics of our patients are shown in Table 1. The majority 
of patients were males (M:F ratio 1.4).The median age of the patients was 48 years (range 16-
84 years), similar in men and  women. In all the analyzed age groups there were more males 
than females except in the group of older than 75 years. The majority of patients were in the 
age group of 46-60 years (33.4%). The majority of patients had normal serum creatinine and 
non-nephrotic proteinuria. The most common indication for renal biopsy was NS (40.3%), 
followed by AUA (31.8%) and CNS (13.9%). Similar results were found in men, whereas in 
women the most common indication was AUA, followed by NS and CNS. Females were 
more prevalent in AUA, ANS and RF syndromes, as shown in Online Resource 1, which also 
shows age distribution according to clinical presentation. The distribution of BPRD in our 
patients is shown in Table 2. The most common diagnoses were IgAGN (19.3%), FSGS 
(15.8%), MGN (9.2%), HERNEF (8.1%) and PCIMUNGN (7.7%). In men, there was a 
similar distribution of BPRD, whereas in women the most common diagnosis was HERNEF 
(13.4%), followed by FSGS (12.9%) and CTDGN (11.6%). The subgroup of miscellaneous 
BPRD included 66 patients (7.2%) and showed following findings: normal renal tissue (20 
patients, 2.2%), mesangioproliferative GN without IgA and IgM deposits (17 patients, 1.8%), 
etiologically non-differentiable focal sclerosing GN (11 patients, 1.2%), findings consistent 
with Gitelman, Bartter or Liddle’s syndrome (5 patients, 0.6%), etiologically non-
differentiable GN caused by immune complexes (4 patients, 0.4%), C1q nephropathy, 
nephronophthisis, nephrocalcinosis and IgM nephropathy (each with 2 patients, 0.2%). 
HERNEF group included 18 patients with Alport syndrome (12 men and 6 women) and 57 
patients with thin membrane disease (10 men and 47 women). The distribution of the most 
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common diagnoses according to gender is shown in Figure 2. The BPRD distribution by age 
groups is shown in Online Resource 2. In age groups 16-30, 31-45 and 46-60 years, the most 
common diagnosis was IgAGN, in the age group of 61-75 years it was PCIMUNGN and in 
the age group of >75 years it was AMORGDEP. Gender and age distribution of BPRD in our 
patients is shown in Figure 5. Men were prevalent in most of the diseases except in MCD, 
HERNEF, CTDGN, DYSGGN, ATIN, CTIN and ESRD. Regarding the age distribution of 
the most common diagnoses, IgAGN was predominantly found in the age group of 16-30 
years (31.7%), FSGS in the age group 31-45 years (24.2%) and MGN in the age group 61-75 
years (31.2%). HERNEF was predominantly found in age group of 31-45 years (36.9%), 
while PCIMUNGN in the age group of 61-75 years (37.1%) (Online Resource 3). Serum 
creatinine and clinical presentation of BPRD in our study is shown in Figure 3.  
Clinicopathological correlations observed in our study are shown in Table 3, while the most 
common diagnoses according to clinical presentation are shown in Figure 4. IgAGN and 
HERNEF presented predominantly as AUA (48.3% and 80.0% respectively), FSGS and 
MGN as NS (51.4% and 82.4%), and PCIMUNGN as ANS (40.8%). In patients with NS the 
most common diagnoses were FSGS (20.2%) followed by MGN (18.8%) and IgAGN 
(10.8%). In patients with AUA the most common BPRD were IgAGN (29.4%), HERNEF 
(20.5%) and FSGS (13.3%). The most common diagnosis in patient with ANS was 
PCIMUNGN (48.3%), in patients with CNS it was IgAGN (28.9%) and in patients with RF 
the most common diagnosis was PCIMUNGN (17.4%), followed by ATI (14.5%) and ATIN 
(13.0%). 
DISCUSSION 
This work represents a 15 years retrospective study on BPRD in the biggest Nephrology 
Department for adult native renal biopsies in Croatia, providing comprehensive information 
about demographics, clinical syndromes and pathohistology of those diseases. In recent years 
there is a steadily increase in the rate of renal biopsies in all available reports, as well as in our 
study. This is a consequence of constantly improving technique, making serious 
complications rare and sparse, and also because of widening the indications for renal biopsy.  
There are numerous published papers describing frequency, histopathological findings and 
clinicoepidemiological correlations from different renal biopsy databases all over the world 
[2-29]. It is not always easy to compare (Online Resource 4) these results mainly because of 
different renal biopsy policies and practice in different countries. Some centers obtain a 
biopsy only when the pathology would alter the therapy, while others, like in our centre, have 
a relatively liberal biopsy policy. We recommend to our patients a renal biopsy in any case 
7 
 
where there are urinary abnormalities suggesting parenchymal renal disease and where there 
are no contraindications. Different renal biopsy policy concerns especially AUA syndrome. 
Consequently in countries where there is a strict biopsy policy, the incidence and prevalence 
of diseases presenting predominantly with AUA (like IgAGN and HERNEF) will be 
underestimated. Regarding AUA syndrome, there are also different definitions of this 
syndrome in different registry and database reports. In some (like ours) it includes non-
nephrotic proteinuria and/or any hematuria [15, 25], while in others [2, 5, 6, 8, 18-20], 
macroscopic hematuria is considered as a separate syndrome. There are also different 
definitions of chronic nephritic syndrome and renal failure syndrome.  
The second reason for discrepancies in the incidences from different countries is the non-
uniform classification of BPRD. The most common glomerular diseases (IgAGN, FSGS, 
MGN, MCD, MPGN) are mainly uniformly defined, while the definition of other BPRD 
shows some difference. There are differences in defining acute postinfectious GN, 
poststreptococcal GN and infection related GN and also in crescentic GN and vasculitides as 
well as in non-inflammatory renal pathology like NAS. Then there are some reports defining 
entities that are not classified in majority of reports. For example, diagnosis of 
mesangioproliferative GN without reference to IF microscopy, and also focal segmental GN, 
endocapillary GN and chronic GN [4], diffuse proliferative GN, sclerosing GN, endocapillary 
proliferative GN and segmental proliferative GN [5, 14]. Our classification is most similar to 
Italian [2, 3], Spanish [6, 7] and Czech [8] report, with some minor differences. In our study, 
the category PCIMUNGN represents primary and secondary crescentic GN type III, because 
in some cases, it is difficult to separate primary from secondary forms of the disease. We also 
separated categories thrombotic microangiopathies (TRMAGP, including malignant 
hypertension) and NAS which are usually aggregated in one category of vascular diseases. All 
mentioned above implies the need for more uniform categorization of clinical syndromes, as 
well as all BPRD for reliable comparison.  
Our results show that men are more prevalent (57.8%) in BPRD, like in virtually all available 
reports, with male prevalence ranging from 50.5% [11] to 65% [2]. The most common 
indication for renal biopsy in our patients was NS in total (40.3%) and also in men (42.6%), 
while in women it was AUA (38.8%). In most registry and database reports, NS was also the 
most common indication [6, 8, 14, 18, 19, 25], while in Italy [2] and in Belgium [20] it was 
AUA. As we stated earlier, this depends on the biopsy policy of different country or region, 
but also on availability of the biopsy and socio-economic status. In comparison of 
clinicoepidemiological data from different countries (Online Resource 4), the age of the 
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included population should also be considered. Some registries and databases include children 
and adults [2, 3, 5, 6, 8, 12, 16], while others include only adults [9, 10, 15, 18-20].  
The most common BPRD in our study were IgAGN (19.3%), FSGS (15.8%) and MGN 
(9.2%), similar to Italy [2, 3], Spain [6], Czech Republic [8], China [16] and South Korea 
[11]. The distribution of BPRD also depends on several factors. First, as already mentioned, 
there is the age of the patients. Consequently, registries with children included, would have 
bigger percentage of predominantly children related BPRD, like MCD or FSGS [5, 6, 12]. 
The race of the included patients should also be an important factor for consideration when 
comparing results from different registries. The distribution of BPRD depends also on renal 
biopsy indications and policies, as mentioned earlier. The next important factor to consider, 
when comparing the BPRD distribution throughout the world, is the use of IF and electron 
microscopy in the analysis of renal biopsy. In some countries, there is no routine use of IF as 
well as electron microscopy. The diagnosis of some very common BPRD directly depends on 
the use of IF microscopy, like IgAGN and PCIMUNGN. In the majority of studies there is no 
exact report on the use of IF, except in the Spain (around 90%) [6], Denmark (78%) [4] and 
Serbia (84%) [18]. The use of electron microscopy is even less frequent according to available 
data: in Italy 38% [2], Spain 23% [6] and Brazil 9% [5]. Electron microscopy is crucial in 
establishing diagnosis of MCD and HERNEF, as well as in differentiating between primary 
and secondary FSGS. We routinely use IF and electron microscopy in the renal biopsy 
analysis in all our patients, and we believe that this is one of the major advantages of our 
study. Consequently, there is a much bigger prevalence of HERNEF (8.1%) in our study 
compared to some others [5, 10, 11, 14-16, 18]. Recent articles showed that electron 
microscopy was absolutely necessary to make a correct diagnosis in 21% of cases, while its 
use resulted in clinically relevant refinement of or addition to the diagnosis in another 24% of 
cases [31, 32]. 
Regarding clinicopathological correlations, the gender distribution of BPRD in our patients 
was as expected. In women, the most common diagnoses were HERNEF (predominantly thin 
membrane disease in 82.5%), FSGS and CTDGN, while in men, the most common were 
IgAGN, FSGS and MGN. From available data, in Italy, in men the most common BPRD were 
IgAGN, NAS and ATI, and in women CTDGN, MCD and FSGS [3], while in Lebanon in 
men and women the most common BPRD was mesangiproliferative GN (including IgAGN) 
and FSGS [27]. Also, in different age groups there was different distribution of BPRD, as 
expected (Figure 4). In patients with NS the most common diagnosis was FSGS (20.2%), 
followed by MGN (18.8%). In most other studies it was reversed, MGN was the most 
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common, followed by FSGS [2, 3, 7, 10]. This could be result of our relative liberal biopsy 
policy, including more patients with AUA, a more likely presentation of FSGS than MGN. In 
patients with AUA the most common BPRD was IgAGN, as in the majority of other studies 
[2, 3, 5, 7]. 
This report shares some limitations common to majority disease registries based on diagnostic 
maneuvers. The study is retrospective, the included patients were from different parts of 
Croatia, referred to our tertiary centre with relatively non-uniform referral policies, depending 
on local expertise and changing indications. However, the information obtained from this 
study is important contribution to the understanding the prevalence and pattern of BPRD in 
Croatia.  
In conclusion, our centre biopsy registry, represent the first step in formation of the Croatian 
national registry and permits comparisons with other active renal biopsy registries in the 
world. It should serve as a source for nephrologists and health care providers to stimulate new 
analysis and investigations and to improve prevention and treatment of BPRD.  
ABBREVIATIONS 
AGBMGN = anti-GBM glomerulonephritis  
AMORGDEP = amyloidosis and other renal diseases with organized deposits  
ANS = acute nephritic syndrome 
APINFGN = acute postinfectious glomerulonephritis  
ATI = acute tubular injury  
ATIN = acute tubulointerstitial nephritis 
AUA = asymptomatic urinary abnormalities 
BPRD = biopsy-proven renal disease 
CNS = chronic nephritic syndrome 
CTDGN = glomerulonephritis associated with connective tissue diseases  
CTIN = chronic tubulointerstitial nephritis 
DMETGN = diabetic nephropathy and metabolic diseases 
DYSGGN = dysgammaglobulinemia associated disorders 
EGFR = estimated glomerular filtration rate 
ESRD = end stage renal disease  
FSGS = focal segmental glomerulosclerosis  
GN = glomerulonephritis 
IgAGN = IgA glomerulonephritis  
HERNEF = hereditary nephritis 
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MCD = minimal change disease   
MGN = membranous glomerulonephritis  
MPGN = membranoproliferative glomerulonephritis  
NAS = nephroangiosclerosis  
NS = nephrotic syndrome 
PCIMUNGN = pauci-immune glomerulonephritis  
TID = tubulointerstitial disease 
TRMAGP =  thrombotic microangiopathy 
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TABLES 
Table 1. Patients distribution according to age, gender, basic laboratory findings and clinical 
presentation 
 
TOTAL  
(N=922) 
Male 
(N=533; 57.8%) 
Female 
(N=389; 42.2%) 
Age (year) 48.0 (36.0-59.0) 48.0 (36.0-59.0) 48.0 (35.0-60.0) 
Age groups (N,Column %)    
16-30 years 145 (15.7) 79 (14.8) 66 (17.0) 
31-45 years 264 (28.6) 151 (28.3) 113 (29.0) 
46-60 years 308 (33.4) 192 (36.0) 116 (29.8) 
61-75 years 186 (20.2) 102 (19.1) 84 (21.6) 
>75 years 19 (2.1) 9 (1.7) 10 (2.6) 
S-Creatinine (µmol/l) 119.0 (86.0-206.0) 129.0 (99.0-217.0) 94.0 (73.0-187.0) 
S-Creatinine groups (N,Column %)    
≤100 µmol/l 418 (45.3) 200 (37.5) 218 (56.0) 
111-200 µmol/l 263 (28.6) 182 (34.1) 81 (20.8) 
201-400 µmol/l 144 (15.6) 92 (17.3) 52 (13.4) 
401-600 µmol/l 49 (5.3) 30 (5.6) 19 (4.9) 
>600 µmol/l 48 (5.2) 29 (5.4) 19 (4.9) 
EGFR (ml/minute) 58.2 (28.4-83.9) 56.2 (28.6-81.4) 60.6 (27.5-87.8) 
EGFR groups (N, Column %)    
≥90ml/minute 178 (19.3) 89 (16.7) 89 (22.9) 
60-89 ml/minute 264 (28.6) 157 (29.5) 107 (27.5) 
30-59 ml/minute 237 (25.7) 150 (28.1) 87 (22.4) 
15-29 ml/minute 131 (14.3) 80 (15.0) 51 (13.1) 
<15 ml/minute or dialysis 112 (12.1) 57 (10.7) 55 (14.1) 
24-hour proteinuria (g) 2.25 (0.77-6.50) 2.70 (0.97-6.50) 1.80 (0.41-6.50) 
24-hour proteinuria groups  
(N, Column %) 
   
<3.5 g/24 hours 560 (60.7) 312 (58.5) 248 (63.8) 
≥3.5 g/24 hours 362 (39.3) 221 (41.5) 141 (36.2) 
Clinical syndrome (N, Column %)    
NS 372 (40.3) 227 (42.6) 145 (37.3) 
AUA 293 (31.8) 142 (26.6) 151 (38.8) 
ANS 60 (6.5) 34 (6.4) 26 (6.7) 
CNS 128 (13.9) 92 (17.3) 36 (9.3) 
RF 69 (7.5) 38 (7.1) 31 (8.0) 
Continuous variables are given as median with interquartile range and categorical variables as 
frequency with column percentage. EGFR = estimated glomerular filtration rate calculated 
according to CKD-EPI formula. 
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Table 2. Biopsy-proven renal disease in our patients  
Diagnosis 
 
ALL 
(N=922) 
 Male 
(N=533) 
 Female 
(N=389) 
MCD 27 2.9%  11 2.1%  16 4.1% 
FSGS 146 15.8%  96 18.0%  50 12.9% 
MGN 85 9.2%  54 10.1%  31 8.0% 
IgAGN 178 19.3%  137 25.7%  41 10.5% 
MPGN 22 2.4%  14 2.6%  8 2.1% 
APINFGN 13 1.4%  9 1.7%  4 1.0% 
HERNEF 75 8.1%  23 4.3%  52 13.4% 
CTDGN 62 6.7%  17 3.2%  45 11.6% 
AGBMGN 2 0.2%  2 0.4%  0 0.0% 
PCIMUNGN 71 7.7%  40 7.5%  31 8.0% 
TRMAGP 10 1.1%  5 0.9%  5 1.3% 
DMETGN 48 5.2%  30 5.6%  18 4.6% 
DYSGGN 14 1.5%  3 0.6%  11 2.8% 
AMORGDEP 17 1.8%  8 1.5%  9 2.3% 
NAS 27 2.9%  19 3.6%  8 2.1% 
ATIN 13 1.4%  6 1.1%  7 1.8% 
CTIN 25 2.7%  11 2.1%  14 3.6% 
ATI 16 1.7%  10 1.9%  6 1.5% 
ESRD 5 0.5%  2 0.4%  3 0.8% 
Miscellaneous 66 7.2%  36 6.8%  30 7.7% 
Data are given as frequency and column percentage. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
15 
 
Table 3. Clinicopathological correlations observed in our patients with biopsy-proven renal disease (N=922) 
Diagnosis 
NS  AUA  ANS  CNS  RF 
N 
Row 
% 
Column 
% 
 
N 
Row 
% 
Column 
% 
 
N 
Row 
% 
Column 
% 
 
N 
Row 
% 
Column 
% 
 
N 
Row 
% 
Column 
% 
MCD 23 85.2% 6.2%  4 14.8% 1.4%  0 0.0% 0.0%  0 0.0% 0.0%  0 0.0% 0.0% 
FSGS 75 51.4% 20.2%  39 26.7% 13.3%  3 2.1% 5.0%  27 18.5% 21.1%  2 1.4% 2.9% 
MGN 70 82.4% 18.8%  11 12.9% 3.8%  0 0.0% 0.0%  4 4.7% 3.1%  0 0.0% 0.0% 
IgAGN 40 22.5% 10.8%  86 48.3% 29.4%  10 5.6% 16.7%  37 20.8% 28.9%  5 2.8% 7.2% 
MPGN 19 86.4% 5.1%  1 4.5% 0.3%  0 0.0% 0.0%  2 9.1% 1.6%  0 0.0% 0.0% 
APINFGN 8 61.5% 2.2%  4 30.8% 1.4%  0 0.0% 0.0%  1 7.7% 0.8%  0 0.0% 0.0% 
HERNEF 8 10.7% 2.2%  60 80.0% 20.5%  1 1.3% 1.7%  5 6.7% 3.9%  1 1.3% 1.4% 
CTDGN 39 62.9% 10.5%  16 25.8% 5.5%  4 6.5% 6.7%  3 4.8% 2.3%  0 0.0% 0.0% 
AGBMGN 1 50.0% 0.3%  0 0.0% 0.0%  0 0.0% 0.0%  0 0.0% 0.0%  1 50.0% 1.4% 
PCIMUNGN 20 28.2% 5.4%  4 5.6% 1.4%  29 40.8% 48.3%  6 8.5% 4.7%  12 16.9% 17.4% 
TRMAGP 1 10.0% 0.3%  3 30.0% 1.0%  1 10.0% 1.7%  3 30.0% 2.3%  2 20.0% 2.9% 
DMETGN 35 72.9% 9.4%  4 8.3% 1.4%  0 0.0% 0.0%  7 14.6% 5.5%  2 4.2% 2.9% 
DYSGGN 3 21.4% 0.8%  2 14.3% 0.7%  0 0.0% 0.0%  3 21.4% 2.3%  6 42.9% 8.7% 
AMORGDEP 13 76.5% 3.5%  2 11.8% 0.7%  0 0.0% 0.0%  2 11.8% 1.6%  0 0.0% 0.0% 
NAS 4 14.8% 1.1%  10 37.0% 3.4%  3 11.1% 5.0%  5 18.5% 3.9%  5 18.5% 7.2% 
ATIN 0 0.0% 0.0%  1 7.7% 0.3%  3 23.1% 5.0%  0 0.0% 0.0%  9 69.2% 13.0% 
CTIN 0 0.0% 0.0%  3 12.0% 1.0%  2 8.0% 3.3%  14 56.0% 10.9%  6 24.0% 8.7% 
ATI 1 6.3% 0.3%  2 12.5% 0.7%  3 18.8% 5.0%  0 0.0% 0.0%  10 62.5% 14.5% 
ESRD 2 40.0% 0.5%  0 0.0% 0.0%  0 0.0% 0.0%  1 20.0% 0.8%  2 40.0% 2.9% 
Miscellaneous 10 15.2% 2.7%  41 62.1% 14.0%  1 1.5% 1.7%  8 12.1% 6.3%  6 9.1% 8.7% 
Total 372 40.3% 100.0%  293 31.8% 100.0%  60 6.5% 100.0%  128 13.9% 100.0%  69 7.5% 100.0% 
NS=nephrotic syndrome; AUA=asymptomatic urinary abnormalities; ANS=acute nephritic syndrome; CNS=chronic nephritic syndrome; 
RF=renal failure. 
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LEGENDS TO FIGURES 
 
 
Fig. 1 The renal biopsy rate in our centre by year 
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Fig. 2 The most common biopsy-proven renal disease in our patients according to gender 
 
 
 
 
 
 
 
 
 
Fig. 3 Estimated glomerular filtration rate (A) and clinical presentation (B) distribution of  
biopsy-proven renal disease in our patients (N=922) 
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Fig. 4 The most common biopsy-proven renal disease in our patients according to clinical 
presentation 
 
 
 
 
 
 
 
